Q1 2025 EPS Estimates for AstraZeneca PLC (NASDAQ:AZN) Lifted by Analyst

AstraZeneca PLC (NASDAQ:AZN) – Stock analysts at Zacks Research boosted their Q1 2025 earnings estimates for AstraZeneca in a research note issued to investors on Wednesday, October 16th. Zacks Research analyst R. Department now expects that the company will earn $1.06 per share for the quarter, up from their prior estimate of $1.05. The consensus estimate for AstraZeneca’s current full-year earnings is $4.07 per share. Zacks Research also issued estimates for AstraZeneca’s Q3 2025 earnings at $1.18 EPS, Q4 2025 earnings at $1.23 EPS, FY2025 earnings at $4.57 EPS, Q1 2026 earnings at $1.19 EPS, Q2 2026 earnings at $1.25 EPS, Q3 2026 earnings at $1.32 EPS and FY2026 earnings at $5.12 EPS.

Other research analysts have also recently issued reports about the stock. Barclays upgraded shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Citigroup upgraded shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Finally, TD Cowen upped their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Stock Up 0.6 %

AZN stock opened at $78.31 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company’s 50 day moving average is $81.26 and its 200 day moving average is $78.04. The stock has a market cap of $242.81 billion, a price-to-earnings ratio of 37.83, a price-to-earnings-growth ratio of 1.44 and a beta of 0.46. AstraZeneca has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The firm had revenue of $12.45 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the prior year, the firm posted $1.08 earnings per share. The company’s revenue for the quarter was up 9.1% on a year-over-year basis.

AstraZeneca Cuts Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were paid a dividend of $0.49 per share. This represents a dividend yield of 1.8%. The ex-dividend date was Friday, August 9th. AstraZeneca’s dividend payout ratio (DPR) is presently 47.34%.

Institutional Trading of AstraZeneca

A number of institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of AstraZeneca by 17.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after purchasing an additional 9,002,450 shares during the period. Capital World Investors lifted its stake in AstraZeneca by 0.3% in the first quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock worth $634,525,000 after acquiring an additional 29,497 shares during the period. Envestnet Asset Management Inc. lifted its stake in AstraZeneca by 16.7% in the second quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock worth $266,565,000 after acquiring an additional 488,644 shares during the period. Clearbridge Investments LLC lifted its stake in AstraZeneca by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after acquiring an additional 186,010 shares during the period. Finally, Fayez Sarofim & Co lifted its stake in AstraZeneca by 4.7% in the first quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock worth $202,588,000 after acquiring an additional 134,784 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.